Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

4046 - Results of a prospective, multicenter, non-interventional trial to analyze disease- and treatment-related effects on the functionality of patients with gastrointestinal tumors ≥ 75 years


08 Oct 2016


Poster Display


Jan Hofmann


Annals of Oncology (2016) 27 (6): 207-242. 10.1093/annonc/mdw371


J. Hofmann1, N. Härtel1, J. Hofmann1, M. Neugebauer1, A. Berger2, S. Zschäbitz2, H. Schulze-Bergkamen3, J. Betge1, S. Belle1, R. Jesenofsky1, N. Schulte1, U. Wedding4, M. Ebert1, J. Chi-Kern1

Author affiliations

  • 1 Ii. Medizinische Klinik, Universitätsklinikum Mannheim, 68167 - Mannheim/DE
  • 2 Medical Oncology, National Center for Tumor Diseases, Heidelberg/DE
  • 3 Department For Internal Medicine 2, Marien-Hospital Wesel, 46483 - Wesel/DE
  • 4 Department For Internal Medicine 2, Klinik fuer Innere Medizin II Klinikum der Friedrich- Schiller-Universitaet, 07743 - Jena/DE


Abstract 4046


Cancer is a disease of the elderly (average age of onset >69yrs). However, there is few data available on treatment- and disease-related interactions with the functional reserve of these patients (pts).


Prospective, multicenter non-interventional trial at two university hospitals in Germany. Included were pts ≥ 75yrs (n = 30) with gastrointestinal tumors receiving chemotherapy “ctx” in the period Q1/2015 - Q1/2016. To objectify the functionality of these pts sequential geriatric assessments (G8-Questionaire, ECOG, IADL, ADL) were performed. The analysis is based on data from 2 patient cohorts (C1: ctx 8 wks, n = 15).


An initial dose reduction tended to stabilize the ADL/IADL of pts with newly initiated ctx (C1) when compared to those pts who received a 100%-dosage initially (p = 0,0986). Less ≥2° toxicities (tox) were detected after initial dose reduction (p = ns). However, at the time of the analysis the tox did not correlate with a deterioration in the IADL or ADL. Pts who started ctx with a pathological G8-Screening ( 8 wks (C2), a continued 100%-dosage did not result in a deterioration in the ADL/IADL (additionally no correlation between tox and the IADL/ADL has been detected). C2 pts with an intial G8 


These data suggest, that dose-escalating strategies maintain the functional reserve of pts ≥75yrs with gastrointestinal tumors. However disease control was the strongest predictor for stabilized functionality.

Clinical trial identification

AIO YMO project

Legal entity responsible for the study



Funded by the government


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings